Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1664-1668

  Barnabe, Cheryl ^a,b   Thanh, Nguyen Xuan ^c   Ohinmaa, Arto ^c   Homik, Joanne ^d   Barr, Susan G ^a,b   Martin, Liam ^a   Maksymowych, Walter P ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

DISEASE ACTIVITY; ECONOMIC EVALUATIONS; HEALTH SERVICES RESEARCH; RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; ALBERTA; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883748560     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201918     Document Type: Article

References (17)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Sem Arthritis Rheum 2011;40:371-88.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
4. Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8. (Pubitemid 41206245)
5. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
6. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
7. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008;18:228-39.
8. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85. (Pubitemid 351898370)
9. Barr SG, Martin L, Chung C., et al Mandatory pharmacosurveillance-a Canadian model for access to therapy and research. Clin Exp Rheumatol 2004;22(5 Suppl 35):S39-43 (Pubitemid 39328354)
10. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
11. Dehejia RH, Wahba S. Propensity score matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151-61.
12. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002;2:358-77.
13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrical 1983;70:41-55.
14. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
15. Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011;25:607-24.
16. Beresniak A, Gossec L, Goupille P, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol 2011;38:439-45.
17. Hallert E, Husberg M, Skogh T. 28-Joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatology (Oxford) 2011;50:1259-67.